Please assess the completion status of the following clinical trial:

Trial Title: RenalGuard System and Contrast Media

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>=18 years~2. Chronic kidney disease (estimated glomerular filtration rate \<=30 ml/min/1.72 m2) and/or~3. Risk score for contrast nephropathy ≥11 (according to the Mehran score; J Am Coll Cardiol 2004; 44: 1393-1399)~Exclusion Criteria:~1. Pregnancy~2. Heart failure (NYHA functional class III-IV)~3. Acute pulmonary edema~4. Acute myocardial infarction~5. Recent (\<=2 days) contrast media exposure~6. Patients enrolled in concomitant studies~7. Administration of theophylline, dopamine, mannitol and fenoldopam.~8. End-stage CKD (patients on chronic dialysis)~9. Systemic hypotension (systolic blood pressure \< 100 mg/dl).~10. Multiple myeloma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Systemic alone therapy group (Type: ACTIVE_COMPARATOR): Systemic alone therapy group will be treated by intravenous sodium bicarbonate plus NAC administration. Patients allocated to the Systemic alone therapy group will receive 154 mEq/l of sodium bicarbonate in dextrose and H2O, according to the protocol reported by Merten et al. (9) The initial i.v. bolus was 3 ml/kg per hour for 1 hour immediately before contrast injection. Following this, patients will receive the same fluid at a rate of 1 ml/kg per hour during contrast exposure and for 6 hours after the procedure. All patients will receive NAC (Fluimucil, Zambon Group SpA, Milan, Italy) orally at a dose of 1200 mg twice daily on the day before and on the day of administration of the contrast agent (total of 2 days. Additional NAC dose (1.2 g) will be administered i.v. during the procedure.
- RenalGuard System group (Type: EXPERIMENTAL): Prophylactic controlled hydration with saline (0.9%) plus N-acetylcystein (NAC; 6 g in total). In the RenalGuard group, an initial bolus (priming) of 250 ml will be administered. In case of left ventricular dysfunction (ejection fraction ≤30%) and/or unstable hemodynamic conditions the bolus will be reduced to 150 ml. Following the initial bolus, furosemide (0.25 mg/kg) will be administered in order to achieve the optimal urine flow (≥300 ml/h). The hydration will be continued throughout the duration of the procedure and will last 4 hours following the procedure. Additional doses of furosemide are allowed in case of decrease of urine flow \<300 ml/h.

Based on this trial design, predict the completion outcome and termination type (if applicable).